5-Amino-1MQ + Lipo-C Research Data

Natural Aminos Research Stack or Formula of the Day

5-Amino-1MQ + Lipo-C

Metabolic Regulation, Lipid Handling & Body-Composition Research Spotlight

Important Formulation Note

“Lipo-C” is not a single standardized molecule or a universally fixed formulation. Compounding-pharmacy and research-market products use different combinations and concentrations. Common versions center on methionine, choline and L-carnitine, often with inositol; some also add dexpanthenol (B5), pyridoxine (B6), arginine, chromium or vitamin B12. Because the exact vial composition was not specified here, this report evaluates the best-supported core Lipo-C concept—methionine + choline + L-carnitine, with inositol where present—and treats claims about the complete blend cautiously. Evidence for one formulation cannot automatically be transferred to every product sold as Lipo-C.

Benefits

5-Amino-1MQ

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT); despite being sold beside peptides, it is not itself a peptide. NNMT uses nicotinamide and the methyl donor S-adenosylmethionine (SAM) to generate 1-methylnicotinamide. The research rationale is that excessive NNMT activity in metabolically active tissue may divert nicotinamide away from NAD+ salvage and consume SAM. In cultured adipocytes, 5-Amino-1MQ reduced the NNMT product 1-MNA, increased intracellular NAD+ and SAM, and suppressed lipogenesis. In diet-induced obese mice, NNMT inhibition reduced body weight, white-adipose mass and adipocyte size and lowered plasma cholesterol without reducing food intake.

A later mouse study combined NNMT inhibition with a reduced-calorie diet and found greater loss of body weight and fat, improved lean-mass-to-body-weight ratio, reduced liver and epididymal fat, and improved hepatic steatosis compared with diet change alone. These results make NNMT inhibition interesting for metabolic and body-composition research, but the central limitation is substantial: published benefit data for 5-Amino-1MQ itself remain preclinical.

Lipo-C

The proposed benefit of Lipo-C comes from combining nutrients that participate in different parts of lipid transport, mitochondrial fatty-acid use, methyl-group metabolism and insulin signaling. L-carnitine transports long-chain fatty acids into mitochondria for beta-oxidation. Choline is required for phosphatidylcholine synthesis and normal hepatic export of triglyceride in very-low-density lipoproteins (VLDL). Methionine participates in one-carbon metabolism and generation of SAM, the major cellular methyl donor. Myo-inositol, when included, participates in phosphoinositide signaling and has human trial evidence for modest improvement in insulin sensitivity and some cardiometabolic measures.

Human evidence is strongest for individual components rather than for a branded or compounded Lipo-C mixture. Meta-analyses of randomized trials report that L-carnitine supplementation produces modest average reductions in body weight, BMI and fat mass, particularly in people with overweight or obesity. Inositol meta-analyses have found modest reductions in BMI and improvements in fasting glucose, insulin and HOMA-IR, although heterogeneity is high. Choline is biologically essential for liver lipid handling; a 2025 randomized controlled trial in Egypt found that phosphatidylcholine added to conventional care for fatty liver improved steatosis-related measurements, liver enzymes, oxidative-stress markers and triglycerides over 12 weeks. These results support the biology of individual ingredients, not proof that an injectable Lipo-C blend causes clinically meaningful fat loss.

What the Formulas Are Studied For

5-Amino-1MQ Research Uses

• NNMT inhibition as a metabolic target in obesity and insulin-resistance research.

• Reduction of adipocyte lipogenesis and alteration of NAD+/SAM-related metabolic flux in cell models.

• Body-weight, white-adipose-tissue and hepatic-fat outcomes in diet-induced obesity models.

• Interaction between pharmacologic NNMT inhibition and calorie reduction in metabolic-disease models.

• More broadly, NNMT as a target in energy homeostasis, adipose biology and age-associated metabolic dysfunction.

Lipo-C / Component Research Uses

• L-carnitine: fatty-acid transport into mitochondria, energy metabolism, exercise physiology and body-composition research.

• Choline: hepatic phosphatidylcholine synthesis, VLDL export, liver-fat biology and one-carbon metabolism.

• Methionine: methyl-donor metabolism, SAM generation, amino-acid balance and liver metabolic pathways.

• Inositol (when present): insulin signaling, glucose homeostasis, PCOS/metabolic research and cardiometabolic outcomes.

• Other optional Lipo-C ingredients such as B5, B6, arginine, chromium or B12 have their own biochemical roles, but their presence varies by formulation and cannot be assumed.

Published Research — Worldwide Evidence Review

5-Amino-1MQ and NNMT

The foundational 2018 U.S. study by Neelakantan and colleagues characterized membrane-permeable NNMT inhibitors, including 5-Amino-1MQ, in adipocytes and diet-induced obese mice. The investigators reported selective NNMT inhibition, reduced 1-MNA, increased NAD+ and SAM in cultured adipocytes, suppressed lipogenesis, and reductions in body weight and white-adipose mass in obese mice. No reduction in food intake was required to produce the mouse effect. This is the key published study behind most current metabolic claims for 5-Amino-1MQ.

A 2021 U.S. Scientific Reports study extended the model by combining NNMT inhibitor treatment with a reduced-calorie diet in obese mice. The combination accelerated body-weight and fat loss and improved hepatic-fat measures relative to diet change alone. Importantly, this was still an animal study. It demonstrates that the pharmacologic mechanism can interact with another metabolic intervention in vivo, but it does not establish a human weight-loss effect or human safety.

Human research does support the target, even though it does not validate 5-Amino-1MQ as a treatment. A study of human adipose tissue found NNMT expression to be approximately twofold higher in omental and subcutaneous fat from people with type 2 diabetes; NNMT expression and plasma 1-MNA tracked with insulin resistance, and both exercise and bariatric surgery were associated with reductions in adipose NNMT expression. This supports NNMT as a biologically relevant metabolic marker in humans, but target association is not the same as proof that pharmacologically blocking NNMT with 5-Amino-1MQ is beneficial.

No published human Phase 1, Phase 2 or Phase 3 efficacy trial of 5-Amino-1MQ was identified in the research reviewed for this report. Consequently, human pharmacokinetics, effective exposure, long-term target effects, drug interactions and a clinically validated safety window remain unresolved.

L-Carnitine — International Human Evidence

L-carnitine has a far larger human evidence base than 5-Amino-1MQ. An Iranian-led 2020 meta-analysis of 37 randomized controlled trials involving 2,292 participants found modest reductions in body weight, BMI and fat mass, while waist circumference and body-fat percentage were not consistently improved. A second meta-analysis of 43 randomized trials similarly found modest weight and BMI reductions, particularly in participants with overweight or obesity. A 2024 Iranian systematic review in type 2 diabetes reported small improvements in BMI, HbA1c, LDL cholesterol, triglycerides and fasting glucose. A newer umbrella meta-analysis incorporating more than 16,000 participants also found modest anthropometric effects, while emphasizing heterogeneity across the underlying literature.

These are oral-supplementation datasets across varied populations and doses. They do not validate a specific injectable Lipo-C formulation, but they do establish that L-carnitine has measurable human metabolic effects under some conditions.

Inositol — Europe and Middle East Evidence

A Spain-led 2019 meta-analysis of 20 randomized controlled trials (1,239 participants) found that inositol-family supplementation reduced fasting glucose, two-hour glucose, fasting insulin and HOMA-IR, suggesting improved insulin sensitivity independent of weight. A 2022 Iranian meta-analysis of 15 controlled trials found a small reduction in BMI, with stronger effects in some subgroups such as people with PCOS and overweight/obesity. A 2025 GRADE-assessed meta-analysis from Iranian and U.S. investigators again found modest improvements in several cardiometabolic measures, while rating parts of the anthropometric evidence low or very low certainty because of heterogeneity.

Choline and Methionine — Liver & One-Carbon Metabolism

Choline and methionine are biologically connected through one-carbon metabolism and hepatic lipid handling. Human and animal research has long shown that choline deficiency can promote liver fat accumulation and liver injury, while choline availability supports phosphatidylcholine synthesis and VLDL export. Reviews from Europe and the Americas describe the choline-methionine-SAM network as central to liver lipid homeostasis, while also warning that deficiency models do not directly prove that giving extra amounts to a replete person will produce fat loss.

A 2025 randomized controlled study from Egypt assigned patients with non-alcoholic fatty liver disease to conventional management with or without phosphatidylcholine for 12 weeks. The choline group showed improvements in controlled attenuation parameter, liver enzymes, oxidative-stress markers and triglycerides. This is meaningful human evidence for choline-related liver biology, but it used oral phosphatidylcholine rather than a Lipo-C injection.

Direct Research on 5-Amino-1MQ + Lipo-C Together

No peer-reviewed animal or human study was identified that directly tested 5-Amino-1MQ together with a Lipo-C formulation, or specifically with the full combination of methionine, inositol, choline and L-carnitine. No published clinical trial was found that compared the stack with either formula alone. Therefore, any claimed synergy between 5-Amino-1MQ and Lipo-C is a mechanistic hypothesis, not a demonstrated treatment effect.

Theory of the Stack — How the Combination Could Work

The mechanistic rationale is more coherent than simply calling both products “fat burners,” because the two approaches act at different levels of metabolism. 5-Amino-1MQ targets an enzyme-regulatory node inside cellular nicotinamide and methyl-donor metabolism. A typical Lipo-C blend supplies nutrient cofactors that support fatty-acid transport, hepatic lipid export and methylation-related pathways. In theory, the stack could therefore influence both the creation/storage of lipid and the handling/use of lipid.

1. Adipocyte Lipogenesis / NNMT Layer

Preclinical 5-Amino-1MQ data suggest that NNMT inhibition can suppress lipid synthesis in adipocytes while preserving intracellular NAD+ and SAM. If that biology translated to humans, the compound could theoretically reduce the tendency of adipose tissue to store newly synthesized lipid and alter cellular energy regulation. This is the most experimental layer of the stack because the translation from mouse to human has not been demonstrated.

2. Mitochondrial Fatty-Acid Transport Layer

L-carnitine provides the carnitine shuttle required to transport long-chain fatty acids across the inner mitochondrial membrane for beta-oxidation. The theoretical complement to NNMT inhibition is straightforward: one arm could reduce lipogenic pressure, while the carnitine arm supports the machinery that oxidizes fatty acids. However, providing more carnitine does not automatically increase fat oxidation if carnitine availability is not the rate-limiting step, which helps explain why human weight-loss effects are modest.

3. Hepatic Lipid Export / Choline Layer

Choline supports phosphatidylcholine production, which is necessary for VLDL assembly and export of triglyceride from the liver. The theoretical stack benefit is not simply greater fat burning; it is potentially improved handling of lipid between liver, circulation and peripheral tissues. This could be relevant where hepatic lipid accumulation is part of the metabolic model. Again, adequate choline status may already satisfy this pathway, so more choline is not guaranteed to create additional benefit.

4. Insulin-Signaling / Inositol Layer

When Lipo-C contains inositol, the stack gains a separate insulin-signaling component. Human trial meta-analyses suggest that inositol can improve insulin sensitivity in selected populations. Better insulin signaling could theoretically complement an NNMT-targeted approach because insulin resistance, adipose NNMT expression and abnormal lipid handling often coexist. The data support inositol as an independent metabolic adjunct; they do not prove that it amplifies 5-Amino-1MQ.

5. One-Carbon / SAM Layer

This is the most scientifically interesting—and most uncertain—interaction. NNMT consumes SAM when methylating nicotinamide. 5-Amino-1MQ is intended to reduce that SAM-consuming reaction. Methionine and choline, meanwhile, feed one-carbon metabolism and methyl-donor availability. In theory, inhibiting an unnecessary SAM drain while maintaining adequate methyl-donor supply could preserve methylation capacity. But one-carbon metabolism is tightly regulated and connected to homocysteine, folate, betaine and many methyltransferases. There is no evidence that adding methionine/choline to 5-Amino-1MQ produces a favorable net SAM or methylation effect in humans.

Possible Overall Benefit — Theoretical, Not Proven

Taken together, the most defensible theoretical purpose of this stack is broader metabolic coverage rather than a single amplified mechanism. 5-Amino-1MQ could, in theory, reduce NNMT-driven lipogenesis and conserve NAD+/SAM-related metabolic capacity; L-carnitine could support mitochondrial fatty-acid transport; choline could support hepatic triglyceride export; methionine could support methyl-donor metabolism; and inositol, if present, could support insulin signaling. A successful combined effect would therefore be expected to look like improved lipid handling, reduced adipose storage pressure and improved metabolic efficiency rather than appetite suppression.

The theory is biologically plausible because the pathways are largely complementary rather than duplicative. The weakness is that each step depends on a different assumption: that NNMT inhibition translates from mice to humans, that the Lipo-C nutrients are limiting enough for supplementation to matter, and that combining the pathways does not create unexpected metabolic feedback. None of those assumptions has been tested in a controlled stack study.

Why More Research Is Needed

• 5-Amino-1MQ lacks published human safety, pharmacokinetic and efficacy trials. This is the largest evidence gap in the entire stack.

• Lipo-C is not standardized. Different products contain different ingredients and concentrations, making the name itself an unreliable research intervention unless the exact formula is specified.

• Human evidence for L-carnitine, inositol and choline comes mainly from oral supplementation studies, not from the exact injectable combinations marketed as Lipo-C.

• No published study has tested 5-Amino-1MQ plus Lipo-C together, so synergy, antagonism, optimal sequencing and interaction risk are unknown.

• The one-carbon metabolism interaction is especially under-studied. NNMT inhibition changes nicotinamide/SAM handling, while methionine and choline influence methyl-donor pools; the downstream effect on homocysteine and global methylation has not been mapped for this combination.

• Long-term outcomes are unknown. A short-term shift in weight, liver fat or biochemical markers would not establish durable metabolic benefit or long-term safety.

• International replication of 5-Amino-1MQ itself is limited. Much of the compound-specific work comes from a relatively concentrated U.S. research program, while the broader international evidence applies to the Lipo-C nutrients rather than the NNMT inhibitor.

Theory vs. Proof — Verdict

What is supported by evidence: NNMT is linked with human insulin resistance and metabolic dysfunction; 5-Amino-1MQ can inhibit NNMT and improve obesity-related endpoints in cell and mouse models; L-carnitine has modest human weight/body-composition evidence; inositol has human evidence for insulin-sensitivity effects; and choline/methionine biology is clearly relevant to hepatic lipid and one-carbon metabolism.

What is not proven: that 5-Amino-1MQ produces weight loss, improved body composition or metabolic benefit in humans; that any specific Lipo-C injection produces clinically meaningful fat loss; or that combining 5-Amino-1MQ with Lipo-C creates an additive or synergistic result.

Verdict — theory vs. proof: the stack has a reasonably strong mechanistic theory because it combines largely non-overlapping metabolic pathways: NNMT/lipogenesis regulation, mitochondrial fatty-acid transport, hepatic lipid export, insulin signaling and methyl-donor metabolism. The proof for the complete stack is weak because there is no direct combination study and the most distinctive member, 5-Amino-1MQ, has no published human efficacy or safety trial. This is best described as a mechanistically coherent metabolic research hypothesis with uneven evidence—human support for several Lipo-C components, preclinical support for 5-Amino-1MQ, and no direct proof for the stack itself.

Selected Sources

• Neelakantan H, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochemical Pharmacology. 2018;147:141-152. PMID: 29155147. DOI: 10.1016/j.bcp.2017.11.007.

• Sampson CM, et al. Combined nicotinamide N-methyltransferase inhibition and reduced-calorie diet normalizes body composition and enhances metabolic benefits in obese mice. Scientific Reports. 2021;11:5637. PMID: 33707534. DOI: 10.1038/s41598-021-85051-6.

• Kannt A, et al. Association of nicotinamide-N-methyltransferase mRNA expression in human adipose tissue and the plasma concentration of its product, 1-methylnicotinamide, with insulin resistance. Diabetologia. 2015. PMID: 25596852.

• Talenezhad N, et al. Effects of L-carnitine supplementation on weight loss and body composition: systematic review and meta-analysis of 37 randomized controlled clinical trials. Clinical Nutrition ESPEN. 2020;37:9-23. PMID: 32359762.

• Askarpour M, et al. Beneficial effects of L-carnitine supplementation for weight management in overweight and obese adults: updated systematic review and dose-response meta-analysis of randomized controlled trials. Pharmacological Research. 2020;151:104554. PMID: 31743774.

• Mirrafiei A, et al. Effects of L-carnitine supplementation on weight loss, glycemic control, and cardiovascular risk factors in patients with type 2 diabetes: systematic review and dose-response meta-analysis. Clinical Therapeutics. 2024;46(5):404-410. PMID: 38594107.

• Miñambres I, et al. Effects of inositol on glucose homeostasis: systematic review and meta-analysis of randomized controlled trials. Clinical Nutrition. 2019. PMID: 29980312.

• Zarezadeh M, et al. Inositol supplementation and body mass index: systematic review and meta-analysis of randomized clinical trials. Obesity Science & Practice. 2022;8(3):387-397. PMID: 35664247.

• Agajani Delavar M, et al. Inositol supplementation efficacy in improving key cardiometabolic and anthropometric indices: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials. Cardiovascular Diabetology. 2025;17(1):411. PMID: 41163174.

• Sedhom SS, et al. The impact of choline supplementation on oxidative stress and clinical outcomes among patients with non-alcoholic fatty liver disease: a randomized controlled study. Therapeutic Advances in Chronic Disease. 2025. PMID: 40838115.

• Mato JM, Martínez-Chantar ML, Lu SC. Methionine metabolism and liver disease. Annual Review of Nutrition. 2008;28:273-293. PMID: 18331185.

• One-Carbon Metabolism and Nonalcoholic Fatty Liver Disease: The Crosstalk between Nutrients, Microbiota, and Genetics. Nutrients. 2019. PMID: 31846961.

• Empower Pharmacy. Lipo-C Injection product information: methionine/choline chloride/L-carnitine/dexpanthenol formulation. Accessed September 2026. Used only to document formulation variability, not as efficacy evidence.

• MediVera Compounding Pharmacy. Lipo-C Injection overview. Accessed September 2026. Used only to document that Lipo-C commonly refers to variable MIC/carnitine-based compounded formulations.

Research Summary

5-Amino-1MQ + Lipo-C is a research stack with a coherent metabolic concept but a sharply uneven evidence base. 5-Amino-1MQ is the experimental component: the NNMT target is biologically relevant in humans, but the compound's demonstrated benefits remain confined to cell and rodent work. Lipo-C is the better human-grounded side only when broken into its individual nutrients, particularly L-carnitine, inositol and choline; the complete compounded blend is not well validated as a weight-loss intervention. The combination is therefore scientifically interesting as a multi-pathway hypothesis, not a proven metabolic therapy.

Research & Educational Use Only !!